Completes Patient Enrollment for ONS-5010/LYTENAVA™ Study

Outlook Therapeutics Completes Patient Enrollment of Open-Label Safety Study for ONS-5010/LYTENAVA™ (bevacizumab-vikg) https://www.channelchek.com/news-channel/Release___Outlook_Therapeutics__OTLK___...read more